Cartesian Therapeutics (RNAC) Earnings Date, Estimates & Call Transcripts $10.41 -0.36 (-3.34%) Closing price 04:00 PM EasternExtended Trading$10.00 -0.41 (-3.94%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cartesian Therapeutics Earnings Summary Cartesian Therapeutics issued Q1 2025 earnings on May 8, 2025, reporting an EPS of -$0.68, which missed the consensus estimate of -$0.61 by $0.07. Quarterly revenue was reported to be $1.10 million, above analyst estimates of $0.69 million. With a trailing EPS of -$52.83, Cartesian Therapeutics' earnings are expected to decrease next year, from $4.56 to ($3.07) per share. Upcoming Q2 Earnings DateAug. 6Before Market OpensEstimatedConsensus EPS (May. 8) -$0.61 Actual EPS (May. 8) -$0.68 Missed By -$0.07 Actual Revenue (May. 8) $1.10MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportSEC FilingRNAC Upcoming EarningsCartesian Therapeutics' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Get Cartesian Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRNAC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RNAC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Cartesian Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.47-$0.47-$0.47Q2 20251-$0.68-$0.68-$0.68Q3 20251-$0.52-$0.52-$0.52Q4 20251-$0.58-$0.58-$0.58 FY 2025 4 -$2.25 -$2.25 -$2.25 Q1 20261-$0.80-$0.80-$0.80Q2 20261-$0.94-$0.94-$0.94Q3 20261-$1.10-$1.10-$1.10Q4 20261-$1.22-$1.22-$1.22 Cartesian Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/8/2025Q1 2025-$0.61-$0.68 -$0.07-$0.68$0.69M$1.10M8/8/2024--$0.81$0.54+$1.35$0.54$6.00M$33.45M5/8/2024Q1 2024-$0.81-$1.97 -$1.16$6.56-$5.84M3/7/2024Q4 2023-$0.30-$2.40 -$2.10$1.23-$8.27M11/13/2023Q3 2023-$1.05-$1.20 -$0.15-$0.10$9.70M$6.55M8/17/2023Q2 2023-$1.35-$1.05+$0.30-$0.07$9.90M$5.25M Cartesian Therapeutics Earnings - Frequently Asked Questions When is Cartesian Therapeutics's earnings date? Cartesian Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on RNAC's earnings history. Did Cartesian Therapeutics beat their earnings estimates last quarter? In the previous quarter, Cartesian Therapeutics (NASDAQ:RNAC) missed the analysts' consensus estimate of ($0.61) by $0.07 with a reported earnings per share (EPS) of ($0.68). Learn more on analysts' earnings estimate vs. RNAC's actual earnings. How can I view Cartesian Therapeutics's earnings report? Cartesian Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Cartesian Therapeutics generate each year? Cartesian Therapeutics (NASDAQ:RNAC) has a recorded annual revenue of $34.17 million. How much profit does Cartesian Therapeutics generate each year? Cartesian Therapeutics (NASDAQ:RNAC) has a recorded net income of -$219.71 million. RNAC has generated -$52.83 earnings per share over the last four quarters. What is Cartesian Therapeutics's EPS forecast for next year? Cartesian Therapeutics's earnings are expected to decrease from $4.56 per share to ($3.07) per share in the next year. More Earnings Resources from MarketBeat Related Companies MLYS Earnings Date PAHC Earnings Date RCUS Earnings Date WVE Earnings Date SNDX Earnings Date COLL Earnings Date ELVN Earnings Date SYRE Earnings Date NRIX Earnings Date ARDX Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal This page (NASDAQ:RNAC) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
